Skip to main content

Clinical Trials Using Cytarabine

Review the clinical trials studying cytarabine on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 76-100 of 106

Venetoclax with Combination Chemotherapy in Treating Patients with Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Chemotherapy (Decitabine in Combination with FLAG-Ida) and Total-Body Irradiation followed by Donor Stem Cell Transplant for the Treatment of Adults with Myeloid Malignancies at High Risk of Relapse
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients with Acute Lymphoblastic Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Brexucabtagene Autoleucel as Consolidation after Inotuzumab, Blinatumomab and Mini-HCVD or HCVAD for the Treatment of Relapsed/Refractory and Newly Diagnosed B-cell Acute Lymphocytic Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Niclosamide in Combination with Cytarabine for Treating Pediatric Patients with Relapsed or Refractory Acute Myeloid Leukemia
Status: Active
Location: Stanford Cancer Institute Palo Alto, Palo Alto, California
Venetoclax Combined with Intensive Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia or Intermediate and Higher Risk Myelodysplastic Syndrome
Status: Active
Location: Montefiore Medical Center-Weiler Hospital, Bronx, New York
CPX-351 with Gemtuzumab Ozogamicin for the Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Ziftomenib with Venetoclax and Gemtuzumab Ozogamicin for the Treatment of Pediatric Patients with Relapsed or Refractory Acute Myeloid Leukemia or Mixed Phenotype Acute Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Combination Chemotherapy (FLAG-Ida) with Pivekimab Sunirine (PVEK [IMGN632]) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Hyper-CVAD in Combination with Venetoclax for the Treatment of Pediatric, Adolescent and Young Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Calaspargase Pegol plus Combination Chemotherapy for the Treatment of Young Adults with Newly Diagnosed Acute Lymphoblastic Leukemia
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
A Study of Melphalan in People with Lymphoma Getting an Autologous Hematopoietic Cell Transplant
Status: Active
Location: Memorial Sloan Kettering Cancer Center, New York, New York
Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML
Status: Active
Location: USC / Norris Comprehensive Cancer Center, Los Angeles, California
Dose Escalation of OXi4503 as Single Agent and Combination With Cytarabine w/Subsequent Ph 2 Cohorts for AML and MDS
Status: Active
Location: See ClinicalTrials.gov
Venetoclax to Augment Epigenetic Modification and Chemotherapy
Status: Active
Location: See ClinicalTrials.gov
Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia
Status: Active
Location: See ClinicalTrials.gov
Combination Chemotherapy with Gemtuzumab Ozogamicin for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
Status: Enrolling by Invitation
Location: University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland
Ziftomenib for the Treatment of Patients with NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy
Status: Approved
Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Universal Donor CD33 CAR Natural Killer Cells for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
Status: Approved
Location: Nationwide Children's Hospital, Columbus, Ohio
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults with Newly Diagnosed B Acute Lymphoblastic Leukemia
Status: Temporarily Closed to Accrual
Location: 428 locations
A Study of Revumenib in Combination with Chemotherapy for Patients Diagnosed with Relapsed or Refractory Leukemia
Status: Temporarily Closed to Accrual
Location: 75 locations
Venetoclax in Combination with Conventional Chemotherapy for the Treatment of Pediatric Patients with Acute Myeloid Leukemia
Status: Temporarily Closed to Accrual
Location: 9 locations
Ponatinib in Combination with Venetoclax and Mini-hyper CVD Chemotherapy for the Treatment of Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
Tazemetostat in Combination with CHOP for Previously Untreated Peripheral T-Cell Lymphoma
Status: Temporarily Closed to Accrual
Location: 3 locations